Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Among patients with follicular lymphoma (n = 149), ORR seemed higher for obinutuzumab than rituximab (44.6% v 33.3%; P = .08). This observation was also demonstrated by a blinded independent review panel that measured a higher ORR for obinutuzumab (44.6% v 26.7%; P = .01). However, this difference did not translate into an improvement in progression-free survival. No new safety signals were observed for obinutuzumab, and the incidence of adverse events was balanced between arms, with the exception of infusion-related reactions and cough, which were higher in the obinutuzumab arm. CONCLUSION:
Obinutuzumab demonstrated a higher ORR without appreciable differences in safety compared with rituximab. However, the clinical benefit of obinutuzumab in this setting remains unclear and should be evaluated within phase III trials.
|
Authors | Laurie H Sehn, Andre Goy, Fritz C Offner, Giovanni Martinelli, M Dolores Caballero, Ole Gadeberg, Tara Baetz, Andrew D Zelenetz, Gianluca Gaidano, Luis E Fayad, Rena Buckstein, Jonathan W Friedberg, Michael Crump, Branimir Jaksic, Pier Luigi Zinzani, Swaminathan Padmanabhan Iyer, Deniz Sahin, Akiko Chai, Günter Fingerle-Rowson, Oliver W Press |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 33
Issue 30
Pg. 3467-74
(Oct 20 2015)
ISSN: 1527-7755 [Electronic] United States |
PMID | 26282650
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | © 2015 by American Society of Clinical Oncology. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antigens, CD20
- Antineoplastic Agents
- Rituximab
- obinutuzumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Antigens, CD20
(biosynthesis)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Lymphoma, B-Cell
(drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Rituximab
(administration & dosage, adverse effects)
|